Condition

Recurrent Chronic Lymphocytic Leukemia clinical trials and research

• 8Clinical trials
• 1Country

Newest Recurrent Chronic Lymphocytic Leukemia clinical trials

All recruiting trials (8)

• Mirdametinib for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

  This phase II trial tests whether the oral MEK inhibitor mirdametinib can shrink or control relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults.

  Recruiting at 9 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 8 other locations · NCT07061951

• Combination treatment for chronic lymphocytic leukemia and lymphoma

  This study is testing a new combination treatment with sonrotoclax and either zanubrutinib or rituximab to see if it can help patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06839053

• Q702 to treat blood cancers

  This Phase 1 trial will test whether the oral drug Q702 is safe, tolerable, and what dose works best for adults with certain blood cancers who have failed or are not eligible for standard treatments.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT06712810

• Treatment using modified T-cells for relapsed or refractory B-cell cancers

  This study is testing a new treatment that uses specially modified T-cells to see if it can help people with hard-to-treat B-cell cancers.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT06191887

• Genetically engineered CAR T-cells for treating certain blood cancers

  This study is testing a new type of treatment using specially modified immune cells to see if they can help people with certain blood cancers that haven't responded to other treatments.

  Recruiting at 2 sites Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT05418088

• Combining acalabrutinib and venetoclax for treating tough cases of chronic lymphocytic leukemia and small lymphocytic lymphoma

  This study is testing if combining two medications, acalabrutinib and venetoclax, can help people with tough cases of chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and improve their treatment results.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT04941716

• CD19 CAR-T cell therapy for treating relapsed B cell cancers

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed B cell cancers feel better.

  Recruiting Phase 1 Mayo Clinic · Rochester, Minnesota · NCT04892277

• Combining acalabrutinib, venetoclax, and possibly obinutuzumab for treating high-risk chronic lymphocytic leukemia

  This study is testing a combination of three medications to see if they can help people with high-risk chronic lymphocytic leukemia feel better and improve their treatment results.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04169737

Related topics

Quick answers

How many Recurrent Chronic Lymphocytic Leukemia clinical trials are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →